Friday 10 March 2017

Coagulation Analyzer Market Expected To Grow At A CAGR Of 10.2% From 2013 To 2024: Grand View Research, Inc.


The global coagulation analyzers/reagents market is expected to reach USD 7.9 billion by 2024, according to a new report by Grand View Research, Inc. Rising technological advancements in coagulation analyzers are expected to be the most impact rendering driver for lucrative growth of the market. Automation is the key development that has occurred in recent years.
The most relevant advancement includes combination of different assay procedures in single equipment and various commercially available hemostasis analyzers, which are capable of performing tests such as Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), D-Dimer, and Fibrinogen as well as these machines can perform chromogenic and immunologic assays.
Moreover, these systems may have the capacity of holding more samples, providing faster results, and increasing the efficiency of laboratory workflow. The advancements in hemostasis analyzers are as follows:
·         Integration of the system with track line systems and work cells, which may improve the reliability of analysis in terms of single detection system and preanalytical check for interfering substances
·         Failure pattern sensors, which detect insufficient sample levels and clots and cap piercing, which enhances safety and sample integrity
·         Automatic reflex testing, repeat testing, and redilution

Further key findings from the study suggest:
  • Clinical laboratory analyzers held over 70.0% of the market share in 2015 and are predicted to sustain its dominance over the forecast period.
  • Advantages such as use of whole blood as sample, no pre-analytical delay and requirement of lesser reagents, further boost growth of Point of Care analyzers.
  • Reagents held the highest market share in 2015. This dominance may be attributed to increasing usage of hemostasis analyzers coupled with easy availability of reagents.
  • Optical technology based hemostasis analyzers held the largest share in 2015 and is expected to grow at a CAGR of over 6.0% over the forecast period.
  • The market is majorly dominated by the prothrombin test. The APTT test is estimated to account for the second largest share in the market in 2015.
  • Hospitals are expected to witness lucrative growth over the forecast period. This can be attributed to high number of hospitals in developing economies.
  • For instance, Mexico has over 4,500 hospitals and out of these 67.0% hospitals are private and remaining 33.0% hospitals are public hospitals.
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the global Coagulation Analyzers & Reagents market on the basis of product, technology, test type, end-use and region.
Product Outlook (Revenue, USD Million, 2013 - 2024)
·         Analyzers
o    Clinical Laboratory Analyzers
o    Point of Care Analyzers   
·         Consumables
o    Reagents
o    Stains
Technology Outlook (Revenue, USD Million, 2013 - 2024)
·         Mechanical
·         Electrochemical
·         Optical
o    Photo optical/Chromogenic/Immuno
o    Others/Nephelometric
·         Others
Test Type Outlook (Revenue, USD Million, 2013 - 2024)
·         APTT
·         D-Dimer
·         Fibrinogen
·         Prothrombin
·         Others
End-Use Outlook (Revenue, USD Million, 2013 - 2024)
·         Hospitals
·         Research Institutes
·         Diagnostic Centers
·         Others
Regional Outlook (Revenue, USD Million, 2013 - 2024)
·         North America
o    U.S.
o    Canada
·         Europe
o    UK
o    Germany
·         Asia Pacific
o    Japan
o    China
·         Latin America
o    Brazil
o    Mexico
·         MEA
o    South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more information visit - http://www.grandviewresearch.com/


Biosimilars Market Was Estimated At USD 3.1 Billion In 2015 And Is Expected To Reach $41.7 Billion By 2024: Grand View Research, Inc.

The biosimilars market is expected to reach USD 41.7 billion by 2024, according to a new report by Grand View Research, Inc. The global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024. The most significant factor leading to the growth of this industry is the fact that major biological drugs are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to cut down healthcare costs across the medical systems in the world, and the favorable clinical outcomes demonstrated through clinical trials for the biosimilar drugs is expected to boost the industry.
For the purpose of this study, the major countries considered are the U.S., Canada, the UK, Germany, India, China, Brazil, and Russia. It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia Pacific.
The industry is segmented on the basis of type of products and applications. With regard to the product type, the recombinant non-glycosylated segment is projected to flourish rapidly during the study period. On the other hand, the recombinant glycosylated proteins segment is estimated to grow at a significant CAGR during the period 2015 to 2024 due to the increasing, wide spread incidence of cancer cases (24 million by 2035), which is identified as the crucial factor driving the growth of this sector.


Further key findings from the study suggest:
  • North America is anticipated to be the fastest growing market during the forecast period. The biosimilars market has gained significant momentum in the U.S., presenting new opportunities for R&D and the manufacturing sector of biosimilars.
  • The European market is the most advanced one as it has been the first to formulate a regulatory pathway and adopt the use of biosimilars for more than 8 years now. Germany accounts for the maximum share in the biosimilars industry, followed by the rest of the European countries (UK, France, Spain, and Italy).
  • The Asia Pacific market is expected to witness a lucrative growth during the period 2015 to 2024. India and China are the key countries identified that are expected to lead the industry growth in the study period.
  • The market for oncology is estimated to soar at a rapid pace in accordance with the increasing incidence of cancer cases in the world. Additionally, the demand for cost-effective cancer treatments is expected to further fuel the industry growth.
  • The biosimilars market comprises several local as well as global players. Some major players of this market include Amgen, Inc., Beacon Ltd., Tea Pharmaceutical Industries Ltd., Merck & Co., Milan, Inc., Dr. Reddy’s Laboratories, Inc., Sandoz, Inc., and Celltrion Healthcare Co., Ltd.
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global biosimilars market on the basis of end-user, application, and region:
Biosimilars Market, by Product (Revenue, USD Million, 2013 - 2024)
·         Recombinant Non-Glycosylated Proteins
o    Insulin
o    Human Growth Hormones
o    Granulocyte Colony-stimulating Factor (G-CSF)
o    Interferons
·         Recombinant Glycosylated Proteins
o    Erythropoietin
o    Monoclonal Antibodies
o    Follitropin
Biosimilars Market, by Application (Revenue, USD Million, 2013 - 2024)
·         Oncology
·         Blood Disorders
·         Growth Hormone Deficiency
·         Chronic and Autoimmune Disorders
·         Others
Biosimilars Market, by Region (Revenue, USD Million, 2013 - 2024)
·         North America
o    U.S.
o    Canada
·         Europe
o    UK
o    Germany
·         Asia Pacific
o    China
o    India
·         Rest of the World
o    Brazil
o    Russia

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more information visit - http://www.grandviewresearch.com/